beta
/Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial
Citation Map
The articles shown here are a subset.See the full list of articles below.

Citing (0)

Cited By (0)